Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04119999
Other study ID # Senior CSA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 16, 2019
Est. completion date February 15, 2024

Study information

Verified date February 2024
Source National University of Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this proposal is to evaluate whether mandibular advancement device (MAD) is non-inferior to continuous positive airway pressure (CPAP) in the treatment of obstructive sleep apnea (OSA) and blood pressure reduction. OSA and hypertension are highly prevalent disorders with profound impacts on health. Apart from improving quality of-life, an effective OSA treatment could improve cardiovascular risk partly through blood pressure reduction, particularly in patients with high cardiovascular risk in whom blood pressure control is often suboptimal. Although CPAP is useful, the high non-acceptance and non-adherence preclude its widespread use. East Asians have a restrictive craniofacial phenotype that predisposes them to OSA and the associated cardiovascular stress. CPAP, while considered the first-line therapy for OSA, has failed to improve cardiovascular outcomes in randomized trials till date because it is poorly tolerated. MADs are oral appliances that correct the restrictive craniofacial phenotype present in East Asians by protruding the lower jaw to reduce upper airway collapsibility. MADs are better tolerated than CPAP, and this may be an important determinant of the overall effectiveness in treating OSA, and thus ameliorating the downstream adverse health outcomes. We hypothesize that MADs are non-inferior to CPAP in treating OSA and reducing cardiovascular risk by blood pressure reduction in East Asians. We will recruit East Asian subjects with hypertension and high cardiovascular risk for polysomnography. Patients diagnosed with OSA (n=220) will be randomized to MAD or CPAP groups in a 1:1 ratio for a treatment duration of 6 months. The primary endpoint is the 24-hour mean blood pressure as determined by ambulatory monitoring. The secondary endpoints include sleep-time systolic BP, target blood pressure, cardiovascular biomarkers, and myocardial remodeling. Association between OSA and silent paroxysmal atrial fibrillation will also be determined. If MADs are shown to be effective, the next step is to evaluate our novel device- drug-eluting MAD that the team is developing.


Recruitment information / eligibility

Status Completed
Enrollment 321
Est. completion date February 15, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Age of at least 40 years 2. Chinese (based on the Identity Card or other Identity Document if the subject is a non-Singapore citizen or permanent resident) 3. Physician diagnosed essential hypertension, on at least 1 medication for BP control 4. High cardiovascular risk, as defined by one or more of the following: (a) diabetes mellitus, (b) stroke, (c) significant coronary artery disease (at least one stenosis of >50% diameter in at least one major epicardial artery), (d) chronic kidney disease, excluding polycystic kidney disease, with an estimated glomerular filtration rate of <60 ml/min/1.73m2, or (e) age of 75 years or older. Exclusion Criteria: 1. Known OSA on treatment 2. Cheyne-Stokes breathing or predominantly central sleep apnea (>50%) 3. Known secondary hypertension: from renal (renal artery stenosis, chronic renal failure); endocrine (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism) or cardiac causes (aortic coarctation) 4. Contraindications to CMR: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF <30ml/min/1.73m2), claustrophobia and pregnant women 5. Contraindications to MAD: <6 to 10 teeth in each arch, inability to advance the mandible and open the jaw widely, pre-existing temporomandibular joint problems, severe bruxism 6. Limited life expectancy (< 1 year) 7. Hypertensive crisis, acute coronary syndromes or acute heart failure in the past 30 days 8. Known AF (not suitable for CMR and affects remodelling analysis)

Study Design


Intervention

Device:
Mandibular Advancement Device
Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
Continuous Positive Airway Pressure
Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA

Locations

Country Name City State
Singapore NUHS Cardiosleep research laboratory Singapore

Sponsors (4)

Lead Sponsor Collaborator
National University of Singapore National Heart Centre Singapore, National University Hospital, Singapore, Ng Teng Fong General Hospital

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other Subgroup analysis Prespecified subgroups include - Age, Gender, BMI, wrist circumference, AHI, ODI, ESS, DM, IHD, number of HT medicine, Device adherence 6 months and 12 months
Primary 24-hour mean BP (24MBP) Difference in 24-hour mean BP (24MBP) between the patients in the MAD and CPAP groups as determined by 24-hour ambulatory BP monitoring. 6 months
Secondary 24-hour systolic BP (24SBP) Difference in 24-hour systolic BP (24SBP) between the patients in the MAD and CPAP groups as determined by 24-hour ambulatory BP monitoring. 6 months and 12 months
Secondary 24-hour pulse pressure (24PP) Difference in 24-hour pulse pressure (24PP) between the patients in the MAD and CPAP groups as determined by 24-hour ambulatory BP monitoring. 6 months and 12 months
Secondary Nocturnal dipping Difference in prevalence of nocturnal dipping between the patients in the MAD and CPAP groups as determined by 24-hour ambulatory BP monitoring. 6 months and 12 months
Secondary Ectopic beat Difference in prevalence of ectopic beats between the patients in the MAD and CPAP groups as determined by continuous ECG monitoring 12 months
Secondary Myocardial remodeling Difference in LV and LA dimensions between the patients in the MAD and CPAP groups as determined by cardiac MRI 12 months
Secondary Epworth Sleepiness Scale (ESS) score Difference in change in ESS score between the MAD and CPAP groups 6 months and 12 months
Secondary Sleep Apnea Quality of Life Index (SAQLI) Difference in change in SAQLI score between the MAD and CPAP groups 6 months and 12 months
Secondary Functional Outcome of Sleep Questionnaire (FOSQ) Difference in change in SAQLI score between the MAD and CPAP groups 6 months and 12 months
Secondary 36-Item Short Form Health Survey (SF-36) Difference in change in SF-36 score between the MAD and CPAP groups 6 months and 12 months
Secondary EuroQol 5Q (EQ5D) Difference in change in EQ5D score between the MAD and CPAP groups 6 months and 12 months
Secondary Daytime systolic BP Difference in change in daytime systolic BP between the patients in the MAD and CPAP 6 months and 12 months
Secondary Nighttime systolic BP Difference in change in nighttime systolic BP between the patients in the MAD and CPAP 6 months and 12 months
Secondary Percentage of patient with 24-hour systolic BP<130 mmHg Difference in percentage of patients with 24-hour systolic BP<130 mmHg in the MAD and CPAP groups 6 months and 12 months
Secondary Percentage of patient with 24-hour systolic BP<120 mmHg Difference in percentage of patients with 24-hour systolic BP<120 mmHg in the MAD and CPAP groups 6 months and 12 months
Secondary NT-proBNP Change in the plasma level of NT-proBNP from baseline to 6-month follow-up 6 months and 12 months
Secondary High sensitivity troponin Change in the plasma level of high sensitivity troponin from baseline to 6-month follow-up 6 months and 12 months
Secondary High sensitive C-reactive protein Change in the plasma level of high sensitive C-reactive protein from baseline to 6-month follow-up 6 months and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05857384 - Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs Phase 1
Recruiting NCT04547543 - Follow-up of Apneic Patients by Visio-consultation N/A
Recruiting NCT05371509 - Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study N/A
Completed NCT02515357 - Mediterranean Diet/Lifestyle Intervention in Obstructive Sleep Apnea N/A
Completed NCT05582070 - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction N/A
Active, not recruiting NCT03189173 - Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea Phase 2
Completed NCT04084899 - The Effect of CPAP on Lung Hyperinflation in Patients With OSA
Completed NCT03032029 - Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
Recruiting NCT04028011 - Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
Recruiting NCT06047353 - Community Health Advocates for Motivating PAP Use in Our Neighborhoods. N/A
Completed NCT05253963 - Acute Effect of CPAP on Weight in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Completed NCT03589417 - Postural Stability, Balance and Fall Risk in Patients With Obstructive Sleep Apnea
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Withdrawn NCT04063436 - Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea N/A
Recruiting NCT05385302 - Sociological Determinants of Positive Airway Pressure Adherence in OSA Patients
Recruiting NCT04572269 - Metabolomics of Obstructive Sleep Apnea
Not yet recruiting NCT06467682 - 12-week Tele-exercise Program in Patients With OSA N/A
Withdrawn NCT04011358 - Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study N/A